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PEGYLATED FILGRASTIM (PF) AFTER HIGH DOSE CHEMOTHERAPY
(HDC) AND AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)
Jagasia, M.H., Greer, J.P., Kassim, A., Mineishi, S., Morgan, D., Ruffner,
K., Schuening, F. Vanderbilt University Medical Center, Nashville, TN
PF (6 mg ﬁxed dose) is equivalent to daily ﬁlgrastim (5 mcg/kg
daily for 14 days) after standard dose chemotherapy in decreasing
the duration of severe neutropenia. Daily ﬁlgrastim (5 mcg/kg)
started within 1-4 days after HDC and ASCT leads to signiﬁcant
decrease in time to neutrophil engraftment (NE). The role of PF
after HDC and ASCT is not known. We propose to study the role
of PF given as a single ﬁxed dose (6 mg) subcutaneoulsy on day 1
after stem cell infusion. Nine patients undergoing HDC and
ASCT using peripheral blood stem cells for multiple myeloma or
lymphoma have been enrolled in an ongoing study. Stem cells were
collected with peripheral blood pheresis after cyclophosphamide (3
g/sq.m) and daily ﬁlgrastim (10 mcg/kg). All patients were eligible
for HDC and ASCT as per institutional criteria and signed an
informed consent. High dose melphalan (200 mg/sq.m) was used
for patients with myeloma. Patients with lymphoma received cy-
clophosphamide (7200 mg/sq.m), BCNU (400 mg/sq.m) and in-
fusional etoposide (2400 mg/sq.m) as their conditioning regimen.
Patients received standard antiinfective prophylaxis per institu-
tional guidelines with acyclovir, levoﬂoxacin and ﬂucanozole start-
ing at day -1. Packed red blood cells (PRBC) were administered for
a hematocrit of less than 25%. Platelets were given for a count of
less than 20,000 thousand/micro.L. There were no adverse events
attributable to PF in these 8 patients. All patients engrafted neu-
trophils and platelets. There were no deaths on study in patients
who received PF. The median time to NE was 10 days (range,
8-11). Incidence of febrile neutropenia was 44% (4/9). Twenty-six
bacterial blood cultures were obtained for febrile episodes or a
suspected line infection, with only 8 (in 5 patients) being positive,
all for coagulase negative staphylococcus. Antibiotics other than
for prophylaxis were required in 56% (5/9) of patients. Antifungals
other than for prophylaxis were not required in any patient. The
median time to platelet engraftment was 17 days (range, 14-19).
The median numbers of transfusions were 3 units of PRBC and 12
units of platelets. The median numbers of days with mucositis and
total parentral nutrition were 3 (range, 0-9) and 3 (range, 0-12),
respectively. Based on this preliminary data, PF at a ﬁxed dose of
6 mg subcutaneoulsy administered on day 1 after HDC and
ASCT appears to be equivalent to daily ﬁlgrastim.
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EQUIVALENT PERIPHERAL BLOOD PROGENITOR CELL COLLECTIONS
WITH DELAYED G-CSF INTRODUCTION IN A CYCLOPHOSPHAMIDE-
CONTAINING MOBILISATION SCHEDULE
Doocey, R.T., Browett, P.J., Norcott, J., Petrasich, M., Hawkins, T.E.
Department of Haematology, Auckland Hospital, Auckland, New Zealand
The role of granulocyte-colony stimulating factor (G-CSF) in com-
bination with chemotherapy is well established in the mobilisation of
peripheral blood progenitor cells (PBPCs) for use in autologous
haematopoietic stem cell transplantation. G-CSF is usually given early
in the mobilisation schedule to allow adequate predictablity of the
optimal time for leucapharesis and to increase PBPC yield whilst
protecting against prolonged chemotherapy induced neutropenia.
There have been limited studies investigating the optimal time of
commencing G-CSF in PBPCmobilization. A later introduction may
allow cost savings from decreased G-CSF dosing without compro-
mising predictability or adequacy of PBSC collection. A prospective
analysis was performed on leucapharesis data for 50 patients (Group
A) who were mobilised with Cyclophosphamide 2 g/m2 followed by
G-CSF (Filgastrim) 5 ug/kg/day administered from Day 6 until com-
pletion of adequate CD34 cell collection. The data was compared
with a historical cohort of 50 patients (Group B) who were mobilized
on a protocol with Cyclophosphamide 2 g/m2 on Day 1 followed by
G-CSF given on Day 2. Patient characteristics were equivalent for
both groups including diagnosis, status of disease and previous cycles
of therapy. The days of G-CSF administration were signiﬁcantly
reduced in Group A as compared to Group B (6 days versus 10 days,
p  0.0001). The total dose of G-CSF per bodyweight was also
signiﬁcantly reduced in Group A (32 ug/kg versus 38 ug/kg, p 
0.007). There was no difference between the two groups in number of
leucopheresis procedures required to obtain a minimum of 2  106
CD34 cells/kg and in overall CD34 cell harvest yields. Group A
was noted to commence initial leucapharesis at one day later than
Group B (Day 12 versus Day 11, p  0.009). There were equivalent
failures of CD34 cell harvesting seen in both groups at 6%. No
mobilisation related sepsis was seen in Group A. Equivalent PBPC
yields can be obtained from the later introduction of G-CSF on Day
6 of a mobilisation schedule that commences with Cyclophosphamide
2 g/m2 onDay 1. This was achieved in our series without any increase
in failures of mobilisation or infection-related sequelae. The de-
creased growth factor consumption has beneﬁcial resource impli-
cations with a potential cost saving per patient mobilised.
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HIGH-DOSE CEB VERSUS BEAM WITH AUTOLOGOUS STEM CELL
TRANSPLANT IN LYMPHOMA
Carrier, E., Wang, E.H., Chen, Y., Castro, J., Ball, E.T., Bashey, A.,
Holman, P., Corringham, S., Lane, T. Rebecca and John Moores UCSD
Cancer Center, School of Medicine, La Jolla, CA
Medical records of 72 patients (pts) who underwent high-dose
chemo w/auto stem cell transplant (HDC-ASCT) conditioned
either CEB (cyclophosphamide 6000 mg/m2, etoposide 2000 mg/
m2, carmustine 600 mg/m2) or BEAM (carmustine 300 mg/m2,
etoposide 800 mg/m2, cytarabine 1600 mg/m2, melphalan 140
mg/m2) between 1/96 7/02 at an institution. 52 pts received CEB
20 pts received BEAM regimen. Pt characteristics include more
males (65%), age 51 years (56%), more NHL (84%) than HD,
63% w/history of complete remission (CR), 33% in CR at time of
HDC-ASCT, 54% in partial remission (PR), the remaining pts in
stable or relapsed status. Tumor grade in pts w/NHL extranodal
involvement were different between the 2 groups (p  0.02, p 
0.03 respectively). History of prior CR, status prior to ASCT were
not signiﬁcant (p  0.09, p  0.09, respectively). Regimen-related
toxicities (RRT) examined yielded diarrhea occurring at a different
frequency after treatment either CEB or BEAM (p 0.003). Cases
occurred in BEAM group (81%) than in CEB group (51%); pts
who received BEAM had milder cases (92%) than CEB (57%).
Difference in the incidence of mucositis was not signiﬁcant (p 
0.12). Pts treated with CEB developed mucositis at a slightly
higher rate (79%) than pts treated with BEAM (75%). Mucositis
occurred within BEAM group was predominately mild (67%) in
contrast to the predominance of moderate to severe cases in CEB
group (74%). All pts who required total parenteral nutrition sup-
port received CEB regimen. Pts treated w/CEB required growth
factor support for longer time than did pts treated w/BEAM (p 
0.04). Four pts (8%) in CEB group 2 pts (11%) in BEAM group
developed BCNU pulmonary toxicity, one was hospitalized. Re-
sponse rate was high in both groups, but no statistical difference
was detected (p  0.09). CEB group, 63% achieved CR 20%
achieved PR. BEAM group, 80% achieved CR and 0% achieved
PR. Survival was higher after treatment with BEAM (84%) than
CEB (60%) (p  0.09) but wasnt statistically signiﬁcant. Time to
death after HDC-ASCT occurred soon in CEB pts than BEAM pts
(p  0.09) but difference didnt reach statistical sugniﬁcance. Time
to disease progression (PD) was different between the 2 treatment
groups (p  0.03). PD occurred frequently in CEB group (38%)
than BEAM group (22%) at a faster rate (31% within 6 mo. in CEB
group versus 6% in BEAM group). Retrospective analysis, pts
conditioned w/BEAM endured less RRT had better survival than
pts conditioned w/CEB.
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OPTIMIZATION OF CHEMO-MOBILIZATION OF AUTOLOGOUS BLOOD
HEMATOPOIETIC PROGENITOR CELL GRAFTS
Hicks, M.L., Lonial, S., Langston, A., Smith, K.J., Mossavi Sai, S.,
Hamilton, E.S., Waller, E.K. Winship Cancer Institute, Emory Uni-
versity School of Medicine, Atlanta, GA
Introduction: Autologous blood hematopoietic progenitor cells
(HPCs) are typically collected by apheresis following chemother-
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